Repare Therapeutics

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

On Thursday, Repare Therapeutics Inc RPTX revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.

Why Is Repare Therapeutics Stock Trading Lower On Friday?

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial.

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial.

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib.

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results.

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting.

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers.

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held in Barcelona, Spain. TRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1/2 dose-escalation.

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expected in Q4 of 2024. Preliminary RECIST response data from 10 patients using the lunresertib + camonsertib combination for ovarian and endometrial cancer patients was 50%. The global ovarian cancer market is expected to reach $11.18 billion by 2029.

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio.

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Participate in Two Upcoming Investor Conferences.

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.28 per share a year ago.

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2024. “We continued to make meaningful progress across our clinical programs in the second quarter and we look forward to a catalyst-rich second half of 2024 that includes the release of data from our ongoing MYTHIC dose expansion clinical trial evaluating the.

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI.

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

BOSTON--(BUSINESS WIRE)--Foundation Medicine announces a collaboration with Repare Therapeutics to provide genomic profiling for Repare's ongoing Phase I/Ib MYTHIC study.

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial. “Camonsertib has demonstrated a promising signal of prolonged progression free survival in patients with ATM-mutated NSCLC in our ongoing TRESR clinical trial. We are.

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lunresertib in combination with camonsertib for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer. Lunresertib in combination with camonsertib is currently being evalu.

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern Time in Miami, FL. A live webcast of the fireside can be accessed in the Investor section of the Company's website at https://ir.

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich,.

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024. “This was a quarter of clinical progress as we await key, near-term data on a rich set of distinctive clinical approaches for our four wholly-owned compounds in 2024,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “We have agreeme.

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial investigating l.

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

News for Repare Therapeutics Stock (RPTX)